Mindray CL-900i assay: An effective assay for hepatitis B surface antigen screening with superior specificity
- PMID: 39877413
- PMCID: PMC11773256
- DOI: 10.1016/j.ijregi.2024.100561
Mindray CL-900i assay: An effective assay for hepatitis B surface antigen screening with superior specificity
Abstract
Objectives: The chemiluminescence immunoassay automated Abbott ARCHITECT hepatitis B surface antigen (HBsAg) screening assay is globally recognized for its superior sensitivity but notably low specificity. This mandates positive results confirmation by another confirmatory assay, such as the widely used Abbott ARCHITECT HBsAg neutralizing assay. This study aimed to evaluate the performance of the new chemiluminescence immunoassay, Mindray CL-900i HBsAg screening assay in comparison to the ARCHITECT neutralizing/confirmatory assay.
Methods: A total of 200 archived HBsAg-positive and -negative samples by ARCHITECT screening were selected for this study. These samples were classified as follows: true positive (n = 39): positive by ARCHITECT screening and confirmatory assays, true negative (n = 144): negative by ARCHITECT screening and confirmatory assays, and false positive (n = 17): positive by ARCHITECT screening but negative by confirmatory assay. All samples were retested using the Mindray CL-900i HBsAg screening assay.
Results: Compared with ARCHITECT confirmatory assay, the Mindray HBsAg CL-900i demonstrated perfect agreement with the confirmatory assay, as indicated by a Cohen κ value of 0.98 (0.95-1.02). Mindray CL-900i exhibited a sensitivity of 97%, positive predictive value of 100%, and negative predictive value of 99%. The specificity was 100% because none of the true-negative and false-positive results were identified as positive.
Conclusions: Mindray CL-900i could offer a cost-effective alternative for HBsAg screening, boasting perfect specificity and overcoming the limitations of current automated assays.
Keywords: Abbott ARCHITECT; CLIA; HBsAg; Mindray CL-900i; Performance.
© 2024 The Authors.
Conflict of interest statement
All the kits used were provided free of charge to support this study from Shenzhen Mindray Biomedical Electronic Co (CL-9000i kits) and the Abbot distributor in Qatar, Khalid Scientific Co. (Architect kits).
Figures

Similar articles
-
Evaluation of the mindray CL900i CLIA HIV Ag/Ab combo assay for sensitive and specific HIV screening compared to established methods.Sci Rep. 2024 Nov 15;14(1):28177. doi: 10.1038/s41598-024-78271-z. Sci Rep. 2024. PMID: 39548153 Free PMC article.
-
Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays.Front Biosci (Landmark Ed). 2021 Jul 30;26(7):198-206. doi: 10.52586/4934. Front Biosci (Landmark Ed). 2021. PMID: 34340267
-
HBsAg blood screening and diagnosis: performance evaluation of the ARCHITECT HBsAg qualitative and ARCHITECT HBsAg qualitative confirmatory assays.Diagn Microbiol Infect Dis. 2011 Aug;70(4):479-85. doi: 10.1016/j.diagmicrobio.2011.03.022. Epub 2011 Jun 11. Diagn Microbiol Infect Dis. 2011. PMID: 21658874
-
Diagnostic performance of hepatitis C virus core antigen testing for detecting hepatitis C in people living with hepatitis B: a systematic review and meta-analysis.Infect Dis Poverty. 2024 Dec 2;13(1):89. doi: 10.1186/s40249-024-01264-7. Infect Dis Poverty. 2024. PMID: 39617947 Free PMC article.
-
New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods.Mol Diagn Ther. 2006;10(2):77-91. doi: 10.1007/BF03256447. Mol Diagn Ther. 2006. PMID: 16669606 Review.
References
-
- World Health Organization (WHO). Hepatitis B, https://www.who.int/news-room/fact-sheets/detail/hepatitis-b; 2022 [accessed 29 December 2024].
LinkOut - more resources
Full Text Sources